Eli Lilly to acquire Dermira for $1.1 billion
16-01-2020
Fed Circ affirms Eli Lilly victories over cancer drugs
13-08-2019
Jonathan Weiss / Shutterstock.com
Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eli, Lilly, Prevail, Therapeutics, genetics, Gaucher, disease, Mark, Mintun, Parkinson, neurodegenerative, dementia, pipeline
